ArticleBMC endocrine disorders2025
Beyond blood pressure and glucose: exploring potential biochemical predictors of cardiovascular disease risk in patients with type 2 diabetes mellitus and co-morbid hypertension.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid-based atherogenic indices and their relationship with cardiovascular disease risk in an African population of type 2 diabetes mellitus patients.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Association between C-reactive protein to albumin ratio and major adverse cardiac events in patients with stable coronary artery disease treated by percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) remains a major cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM), particularly when complicated by hypertension. This study explored markers of glycaemic control, systemic inflammation, and lipid-related atherogenicity, and their relationship with CVD risk among a population of Nigerian patients with T2DM and co-morbid hypertension.
methodThis hospital-based cross-sectional analytical study was conducted over a period of 13 months among patients with T2DM, including those with co-morbid hypertension. The 10-year estimated CVD risk was determined using the WHO CVD risk assessment chart validated for Western sub-Saharan Africa, while glycated haemoglobin (HbA1c), atherogenic index of plasma (AIP), and high-sensitivity C-reactive protein (hsCRP) were assessed as markers of glycaemic control, atherogenicity, and inflammation, respectively. Statistical analyses, including binary logistic regression, were conducted using SPSS version 25, with significance set at p < 0.05.
resultsHypertensive patients with T2DM had significantly higher hsCRP (2.57 mg/L, IQR: 2.63 vs. 0.86 mg/L, IQR: 1.72; p < 0.001) and AIP (0.071, IQR: 0.39 vs. 0.002, IQR: 0.34; p = 0.015). They also had significantly higher mean WHO CVD risk scores (11.3 ± 4.7 vs. 7.2 ± 4.1; p < 0.001), with 60.0% (n = 75) classified as moderate-to-high risk. However, after adjusting for potential confounders in the multivariable analysis, HbA1c (OR = 0.82, p = 0.062), hsCRP (OR = 1.01, p = 0.905), and AIP (OR = 2.22, p = 0.293) did not emerge as significant predictors.
conclusionAlthough hsCRP and AIP levels were elevated in higher CVD risk categories, they did not independently predict risk among patients with T2DM and hypertension. This highlights the limited utility of traditional biochemical markers in this group and the need for early risk assessment and aggressive blood pressure control. Further multicentre studies are needed to validate these results and inform targeted interventions in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.